Clinical Trial Search

Primary: Complete Clinical Response (CCR) of Lesion at Days 50, 100 and 180 (+7 Days) — 47; 30; 3; 12 Participants

Primary: True Positive — 0 samples

Primary: Safety: Overview of Adverse Events — 16; 7; 0; 0 Participants

Primary: Complete Clinical Response — 85; 103; 86 participants

Primary: Date of Clinical Cure — 2; 2; 15; 10 participants

Primary: Percent of Participants With Final Clinical Cure — 78.6; 77.8 percent of participants

Primary: Final Clinical Cure Rate — 101; 102; 73 participants — p=0.0001

Primary: The Primary Safety Endpoint - Frequency of Complications of Therapy — 414 participants

Primary: Equivalence of Efficacy Assessed by the Number of Participants With Clinical Cure — 22; 18; 5; 9 Participants

Primary: Number of Participants That Discontinued Due to Adverse Experience, by Type of Adverse Experience — 12; 10; 3; 1 Participants

Primary: Number of Participants Who Obtained Final Clinical Cure of Index Lesion — 9; 13 Participants

Primary: Positive Result Comparison: CL Detect Rapid Test With Microscopy and Culture Results — 147; 144; 96 Participants

Primary: Number of Participants With Clinical Cure of Lesions — 3 Participants

Primary: Final Clinical Cure for Index Lesions — 11; 9 participants

Primary: Sensitizing Effects of LtSTA in Leishmania Naive Adults — 8; 22; 9 participants

Primary: Probability of Relapse-free Survival — 79; 71 percentage probability

Primary: Number of Differentially Expressed Genes Between Bitten (Case) Versus Unbitten (Control) Skin for Each of the Three Vector Groups — 18; NA; 1; NA number of…

Primary: Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram — 0; 3; 1; 5…

Primary: The Number of Participants That Tolerated the Maximum Drug Dose — 8; 4 Participants

Primary: Clinical Response — 32; 25; 28 Participants

Primary: Cross-reactive Antigenemia — 12 Participants

Primary: Percentage of Subjects Who Correctly Answered a Knowledge Assessment Item Immediately Before and After an Educational Lecture — 52; 94; 19; 90 percentage of participants

Primary: Change in Modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (mCAILS) — 11.0 score on a scale

Primary: Measurement of Change in Early and Late Innate Immune Responses Using Gene Expression and Flow Cytometry in Participants' Skin — 50; 5 % of total dendritic cells

Primary: Number of Participants With Local Adverse Events (AEs) — 7; 1; 0; 0 Participants

Primary: Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions — -8.4…

Primary: Number of Participants With Emergent Chemistry Results by Potential Clinical Importance (PCI) Criteria — 0; 11; 0; 10 Participants

Primary: The Absence of Lentigo Maligna (LM) at the Time of Staged Excisions in Participants — 27; 29 participants

Primary: Global PCR (Conventional PCR and Real-time Quantitative PCR) Immediately After the End of Treatment. — 16; 20 Participants

Primary: Change in Mean Necrobiosis Lipoidica (NL) Lesion Score — -2.7 score on a scale — p=0.005